Investigating Hybrid PLGA-Lipid Nanoparticles as an Innovative Delivery Tool for Palmitoylethanolamide to Muscle...

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Palmitoylethanolamide (PEA) is an endogenous lipid mediator with potential in inflammatory muscle disorders.
• Poor solubility and bioavailability limit PEA's clinical application, particularly for sarcopenia.
• Novel drug delivery systems are needed to enhance PEA's therapeutic efficacy.

Purpose of the Study:

• To develop and characterize hybrid nanoparticles (Hyb-np) for improved Palmitoylethanolamide (PEA) delivery.
• To evaluate the encapsulation, release kinetics, and cellular uptake of PEA-loaded hybrid nanoparticles (PEA-Hyb-np).
• To assess the potential of PEA-Hyb-np for muscle-targeted therapeutic applications.

Main Methods:

• PEA-Hyb-np were synthesized using a modified single-emulsion solvent evaporation method with PLGA and lipid components.
• Nanoparticle characterization involved size, PDI, zeta potential, DSC, FT-IR, and XRD analyses.
• Biological evaluation included cytocompatibility, cellular uptake studies in C2C12 myoblasts, and drug release assays.

Main Results:

• PEA-Hyb-np exhibited optimal particle size (~150 nm) and high encapsulation efficiency (79%) and drug loading (44.2 mg/g).
• Drug amorphization within the nanoparticles enhanced drug release in various media.
• Studies confirmed nanoparticle cytocompatibility, efficient cellular uptake, and improved cell viability.

Conclusions:

• PEA-Hyb-np demonstrate a promising platform for enhancing PEA solubility and bioavailability.
• The developed hybrid nanoparticles show potential for targeted delivery in muscle-related inflammatory conditions.
• This approach could improve the therapeutic efficacy of PEA for sarcopenia and other muscle disorders.